Controlling clostridium difficile

Australian Prescriber

Volumn 36, Issue 4, 2013, Pages 121-124

  McFarlane, Mark ^a   Hajkowicz, Krispin ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antibiotics; Colitis; Diarrhoea; Infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFALEXIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CYCLOPHOSPHAMIDE; DICLOFENAC; DOXORUBICIN; FLUOROURACIL; GATIFLOXACIN; GLUTAMATE DEHYDROGENASE; HISTAMINE H2 RECEPTOR ANTAGONIST; LOPERAMIDE; METHOTREXATE; METRONIDAZOLE; MOXIFLOXACIN; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP; ARTICLE; ASYMPTOMATIC DISEASE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIURIA; CAUSE OF DEATH; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG DOSE REDUCTION; DRUG MISUSE; DRUG MONITORING; DRUG RESPONSE; DYSPEPSIA; ENZYME IMMUNOASSAY; EPIDEMIC; FECES ANALYSIS; FLUID INTAKE; HEALTH PROGRAM; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; MORTALITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; RECURRENT INFECTION; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SKIN ABSCESS; TOXIN ANALYSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 84881057107     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2013.046     Document Type: Article

References (28)

1. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev 1982;46:86-94.
2. Cheng AC, Ferguson JK, Richards MJ, Robson JM, Gilbert GL, McGregor A, et al. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med J Aust 2011;194:353-358.
3. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693-1703.
4. Centers for Disease Control and Prevention. Surveillance for community-associated Clostridium difficile - Connecticut, 2006. MMWR Morb Mortal Weekly Rep 2008;57:340-343.
5. Murphy SL, Xu JQ, Kochanek KD. Deaths: Preliminary data for 2010. National vital statistics reports; vol 60 no 4. Hyattsville, MD: National Center for Health Statistics; 2012.
6. Bull AL, Worth LJ, Richards MJ. Implementation of standardised surveillance for Clostridium difficile infections in Australia: initial report from the Victorian Healthcare Associated Infection Surveillance System. Intern Med J 2012;42:715-718.
7. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012;107:89-95.
8. Stuart RL, Marshall C. Clostridium difficile infection: a new threat on our doorstep. Med J Aust 2011;194:331-332.
9. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-2449.
10. Richards M, Knox J, Elliott B, Mackin K, Lyras D, Waring LJ, et al. Severe infection with Clostridium difficile PCR ribotype 027 acquired in Melbourne, Australia. Med J Aust 2011;194:369-371.
11. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008;62:388-396.
12. Valiquette L, Cossette B, Garant M-P, Diab H, Pépin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007;45 Suppl 2:S112-S121.
13. National Safety and Quality Health Service Standards. Sydney: Australian Commission on Safety and Quality in Health Care; 2011.
14. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:1011-1019.
15. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012;107:1001-1010.
16. Molloy D, Molloy A, O'Loughlin C, Falconer M, Hennessy M. Inappropriate use of proton pump inhibitors. Ir J Med Sci 2010;179:73-75.
17. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010.
18. Suissa D, Delaney JA, Dial S, Brassard P. Non-steroidal anti-inflammatory drugs and the risk of Clostridium difficile-associated disease. Br J Clin Pharmacol 2012;74:370-375.
19. Ferguson JK, Cheng AC, Gilbert GL, Gottlieb T, Korman T, McGregor A, et al. Clostridium difficile laboratory testing in Australia and New Zealand: national survey results and Australasian Society for Infectious Diseases recommendations for best practice. Pathology (Phila) 2011;43:482-487.
20. Cardona DM, Rand KH. Evaluation of repeat Clostridium difficile enzyme immunoassay testing. J Clin Microbiol 2008;46:3686-3689.
21. Huang H, Weintraub A, Fang H, Nord CE. Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections. J Clin Microbiol 2009;47:3729-3731.
22. Peterson LR, Manson RU, Paule SM, Hacek DM, Robicsek A, Thomson RB Jr, et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin Infect Dis 2007;45:1152-1160.
23. Sharp SE, Ruden LO, Pohl JC, Hatcher PA, Jayne LM, Ivie WM. Evaluation of the C.Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of clostridium difficile disease. J Clin Microbiol 2010;48:2082-2086.
24. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-307.
25. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-431.
26. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008;1:CD004611.
27. Johnston BC, Ma SS, Goldenberg JZ, Thorlund K, Vandvik PO, Loeb M, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012;157:878-888.
28. Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-415.